Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
An erratum to this article was published (RMD Open, 27 Jan 2025 ↗)
Authors' conclusion
In FINCH 4, filgotinib 200 mg and 100 mg (continuous or de novo) demonstrated sustained efficacy up to week 156 in patients enrolled from FINCH 1, 2 or 3, with no unexpected safety results.
Study context
- Population
- Patients with rheumatoid arthritis (RA) from FINCH 1, 2 or 3; results shown for MTX inadequate responders
- Comparison
- Filgotinib 200 mg vs 100 mg, continued from FINCH 1, 2 or 3 or de novo
- Outcome
- ACR20 (MTX inadequate responders)
- Follow-up
- Up to week 156
Methodological detailsongoing, interim analysis, non-responder imputation
- Ongoing
- Interim analysis
- Non-responder imputation
Main finding
As reported in the abstract
Further findings
| Outcome | De novo filgotinib 200 mg | De novo filgotinib 100 mg |
|---|---|---|
| Boolean remission 1.0 (MTX inadequate responders) · up to week 156 | 18.8% | 15.4% |
| Boolean remission 2.0 (MTX inadequate responders) · up to week 156 | 21.1% | 18.5% |
Efficacy in patients from FINCH 2 and 3
- Similar efficacy data
Original publication
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study. RMD Open. Published 24 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →